← Peptide library
Peptide comparison
This page compares CJC-1295 and Ipamorelin side by side, drawing on the published reference data for each compound. Both are research peptides, and the points below summarize how each is characterized in its respective cited human studies. The aim is to lay out the reference details for both in one place, not to endorse either one.
CJC-1295
Ipamorelin
Investigational; not FDA-approved
Investigational/discontinued; not FDA-approved
Published Phase 1 human studies
Published Phase 2 human RCT; negative primary endpoint
Subcutaneous (CJC-1295 with DAC in cited study)
Intravenous in cited trial
Single or study-scheduled
Twice daily (IV study)
30–60 mcg/kg
0.03 mg/kg
Key differences
On regulatory status, both are investigational and neither is FDA-approved, though Ipamorelin is additionally noted as discontinued. Their evidence tiers differ: CJC-1295 is backed by published Phase 1 human studies, while Ipamorelin’s cited record is a published Phase 2 human randomized controlled trial whose primary endpoint was not met.
Reference comparison only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol.
Frequently asked questions
How are CJC-1295 and Ipamorelin administered in the cited studies?
They differ. The CJC-1295 figures here come from a subcutaneous study of CJC-1295 with DAC, while the Ipamorelin figures come from an intravenous clinical trial. Both are investigational and not FDA-approved.
What dose figures does this comparison reference?
Weight-based study figures shown above — CJC-1295 30–60 mcg/kg and Ipamorelin 0.03 mg/kg. These come from the cited research and are reference figures only, not dosing recommendations.
Can I calculate reconstitution for both here?
Yes — open either compound’s calculator from the buttons above to convert your own inputs into concentration (mg/mL), draw volume and U-100 syringe units.
Does this page recommend one over the other?
No. Both are investigational research peptides. This page is a neutral reference and does not assess efficacy, safety, or suitability — those decisions belong with a qualified professional.